Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington's Disease

Cells. 2022 Aug 27;11(17):2662. doi: 10.3390/cells11172662.


Huntington's disease (HD) is a rare neurodegenerative disease that is accompanied by skeletal muscle atrophy and cardiomyopathy. Tissues affected by HD (central nervous system [CNS], skeletal muscle, and heart) are known to suffer from deteriorated cellular energy metabolism that manifests already at presymptomatic stages. This work aimed to test the effects of peroxisome proliferator-activated receptor (PPAR)-γ agonist-rosiglitazone on grip strength and heart function in an experimental HD model-on R6/1 mice and to address the mechanisms. We noted that rosiglitazone treatment lead to improvement of R6/1 mice grip strength and cardiac mechanical function. It was accompanied by an enhancement of the total adenine nucleotides pool, increased glucose oxidation, changes in mitochondrial number (indicated as increased citric synthase activity), and reduction in mitochondrial complex I activity. These metabolic changes were supported by increased total antioxidant status in HD mice injected with rosiglitazone. Correction of energy deficits with rosiglitazone was further indicated by decreased accumulation of nucleotide catabolites in HD mice serum. Thus, rosiglitazone treatment may not only delay neurodegeneration but also may ameliorate cardio- and myopathy linked to HD by improvement of cellular energetics.

Keywords: Huntington’s disease; cardiomyopathy; energy metabolism; molecular mechanisms; myopathy; rosiglitazone; therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Disease Models, Animal
  • Huntington Disease* / drug therapy
  • Huntington Disease* / metabolism
  • Mice
  • Mice, Transgenic
  • Muscle, Skeletal / metabolism
  • Neurodegenerative Diseases* / metabolism
  • PPAR gamma / metabolism
  • Rosiglitazone / pharmacology
  • Rosiglitazone / therapeutic use


  • PPAR gamma
  • Rosiglitazone

Grants and funding

This research was supported by the National Science Centre in Poland (number 2016/23/B/NZ4/03877 and number 2015/17/N/NZ4/02841).